The Plaintiff's Steering Committee ("PSC"), State Liaison Committee ("SLC") and Defense Counsel in the Propulsid Federal Multi-District Litigation (MDL-1355, E.D. La.) have agreed to a Supplemental Agreement Re Propulsid MDL 1 and 2 ("Supplemental Agreement") and an Amendment to Term Sheet ("Amendment") to the MDL 1 and MDL 2 Term Sheets executed on April 30, 2004 and December 1, 2005, respectively, related to the resolution of claims arising out of the use of the product Propulsid (cisapride).

The Amendment provides an opportunity for certain Tier I and Tier II claimants whose claims are found ineligible originally by the Medical Panel to have their claims reviewed a second time. Requests for a second review shall be selective, for good cause, and shall not exceed thirty-three and one-third (33 1/3%) percent of the then reviewed Tier I and Tier II claims. No additional or supplemental records, memorandum or other materials shall be submitted or considered as a part of the reconsideration request. The Medical Review Panel Members will be different from those who performed the first review and shall review the claim in the same manner as provided in the original Term Sheet.

The Supplemental Agreement provides that MDL 1 Resolution Program claimants shall have until December 1, 2007 to deliver their Sections 13(A) and 13(B) memoranda to the Special Master.

The Amendment also provides that the deadline for enrolling in the MDL 2 Resolution Program has been extended to December 1, 2007. Enrollees in the MDL 2 Resolution Program who served their enrollment forms before the date of minimum enrollment (October 31, 2006) shall have until December 1, 2007 within which to serve their claim forms. Enrollees who serve their enrollment forms after October 31, 2006 shall have 120 days from the date of such service of their enrollment forms within which to serve their claim forms, or until October 31, 2007, whichever is later.

Please feel free to visit the court's website located at http://Propulsid.laed.uscourts.gov for the entire Supplemental Agreement and Amendment to MDL 1 and MDL 2 Term Sheets.